Technology Review - Published By MIT
Advertisement
TO READ THIS STORY - you must have a paid subscription to Technology Review OR you can purchase special archive reading credits here. Choose from these great offers below.
I'm a paid subscriber please
log me in
I want to purchase this article for
only $1.99
(requires login)
I want to purchase five articles for
only $7.99
(requires login)
I want to buy
1 Year TOTAL Access for
only $24.95
(requires login)

Please note: Click here if you are currently a Technology Review print or digital subscriber and do not have access to this article.

Click here if you are an MIT alum and do not have access to this article.

September 2003

Target: Rogue Immune Cells

DNA-derived vaccine advances on MS.

By Erika Jonietz

Drugs for autoimmune diseases like multiple sclerosis, type 1 diabetes, and rheumatoid arthritis provide relief from symptoms but don't address causes. Researchers now hope to change that with an emerging class of vaccines made from DNA that shut down the immune cells that go awry in these diseases. Early results have been so promising that human trials for the first treatment-a multiple sclerosis therapy that made paralyzed mice walk again-will begin early next year.

Select from the choices above
to read the entire article.


Log In

Forgot your password?     Register »
Advertisement

Videos

Ultra-Efficient Gas Engine Passes Test
Technology Review March/April 2010

Current Issue

TR50
TR presents the 50 most innovative public and private companies of the year.
Advertisement
Advertisement
Advertisement
Subscribe to Technology Review's daily e-mail update. Enter your e-mail address

TECHNOLOGY RESOURCES

More Technology News from Forbes

Advertisement
MIT Massachusetts Institute of Technology © 2010 Technology Review. All Rights Reserved.